此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

针对哮喘不受控制的成年参与者的 FF/UMEC/VI 与非 ellipta 常规护理 ICS-LABA 的务实开放标签随机临床试验 (PERFORM)

2026年9月11日 更新者：GlaxoSmithKline

第 4 期、52 周（24 周时的初步分析）、随机、分层、开放标签、活性对照、平行组、有效性研究，比较 FF/UMEC/VI 与非 ellipta 常规护理 (ICS/ LABA）在哮喘不受控制的成人参与者中的应用

The goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult participants with uncontrolled asthma

研究概览

地位

主动，不招人

条件

干预/治疗

研究类型

介入性

注册 (实际的)

1358

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 中国
      • Nanshan District、中国、518067
        • GSK Investigational Site
      • Zhuhai、中国、519099
        • GSK Investigational Site
    • Foshan City
      • Chancheng District、Foshan City、中国、528031
        • GSK Investigational Site
    • Guangzhou
      • Liwan District、Guangzhou、中国、510160
        • GSK Investigational Site
    • Jiangmen City
      • North Street、Jiangmen City、中国、52900
        • GSK Investigational Site
  • 加拿大
    • Ontario
      • Windsor、Ontario、加拿大、N8X 1T3
        • GSK Investigational Site
    • Quebec
      • Trois-Rivières、Quebec、加拿大、G9A 4P3
        • GSK Investigational Site
  • 台湾
      • Kaohsiung City、台湾、807
        • GSK Investigational Site
      • Taichung、台湾、40447
        • GSK Investigational Site
      • Taichung、台湾、407219
        • GSK Investigational Site
      • Taipei、台湾、10002
        • GSK Investigational Site
  • 日本
      • Fukuoka、日本、807-8555
        • GSK Investigational Site
      • Fukuoka、日本、820-8505
        • GSK Investigational Site
      • Fukuoka、日本、816-0813
        • GSK Investigational Site
      • Fukuoka、日本、832-0059
        • GSK Investigational Site
      • Fukuoka、日本、802-0083
        • GSK Investigational Site
      • Gifu、日本、509-6134
        • GSK Investigational Site
      • Hiroshima、日本、730-0853
        • GSK Investigational Site
      • Hiroshima、日本、730-0013
        • GSK Investigational Site
      • Hiroshima、日本、733-0002
        • GSK Investigational Site
      • Hyōgo、日本、651-0053
        • GSK Investigational Site
      • Kagawa、日本、761-8073
        • GSK Investigational Site
      • Kagoshima、日本、890-0053
        • GSK Investigational Site
      • Kanagawa、日本、252-0143
        • GSK Investigational Site
      • Kumamoto、日本、860-8556
        • GSK Investigational Site
      • Kumamoto、日本、862-0965
        • GSK Investigational Site
      • Matsuyama、日本、790-0925
        • GSK Investigational Site
      • Miyagi、日本、980-0871
        • GSK Investigational Site
      • Miyazaki、日本、880-2112
        • GSK Investigational Site
      • Miyazaki、日本、889-4304
        • GSK Investigational Site
      • Nagaoka-Shi、日本、940-0087
        • GSK Investigational Site
      • Niigata、日本、950-0088
        • GSK Investigational Site
      • Okawa-shi、日本、831-0016
        • GSK Investigational Site
      • Shinjuku-kuTokyo、日本、160-0021
        • GSK Investigational Site
      • Tokyo、日本、160-0017
        • GSK Investigational Site
      • Tokyo、日本、142-8666
        • GSK Investigational Site
      • Tokyo、日本、157-0066
        • GSK Investigational Site
      • Tokyo、日本、173-8606
        • GSK Investigational Site
      • Tokyo、日本、145-0063
        • GSK Investigational Site
      • Tokyo、日本、105-0001
        • GSK Investigational Site
      • Yokohama、日本、223-0053
        • GSK Investigational Site
      • Ōita、日本
        • GSK Investigational Site
  • 澳大利亚
    • Australian Capital Territory
      • Bruce、Australian Capital Territory、澳大利亚、2617
        • GSK Investigational Site
    • New South Wales
      • Blacktown、New South Wales、澳大利亚、2148
        • GSK Investigational Site
      • Coffs Harbour、New South Wales、澳大利亚、2450
        • GSK Investigational Site
      • Kanwal、New South Wales、澳大利亚、2259
        • GSK Investigational Site
      • Sydney、New South Wales、澳大利亚、2035
        • GSK Investigational Site
    • Queensland
      • Brisbane、Queensland、澳大利亚、4006
        • GSK Investigational Site
    • Western Australia
      • Osborne Park、Western Australia、澳大利亚、6017
        • GSK Investigational Site
      • Spearwood、Western Australia、澳大利亚、6163
        • GSK Investigational Site
  • 美国
    • Alabama
      • Centreville、Alabama、美国、35042
        • GSK Investigational Site
    • Arkansas
      • Little Rock、Arkansas、美国、72205
        • GSK Investigational Site
    • California
      • Newport Beach、California、美国、92663
        • GSK Investigational Site
    • Delaware
      • Newark、Delaware、美国、08901
        • GSK Investigational Site
    • Florida
      • Clearwater、Florida、美国、33765-2150
        • GSK Investigational Site
      • Miami、Florida、美国、33126
        • GSK Investigational Site
      • Miami、Florida、美国、33135
        • GSK Investigational Site
      • Miami、Florida、美国、33173-3484
        • GSK Investigational Site
      • North Miami Beach、Florida、美国、33169
        • GSK Investigational Site
      • Orlando、Florida、美国、32819
        • GSK Investigational Site
      • Palm Springs、Florida、美国、33406
        • GSK Investigational Site
      • Port Charlotte、Florida、美国、33952
        • GSK Investigational Site
      • Tallahassee、Florida、美国、32308
        • GSK Investigational Site
    • Illinois
      • Normal、Illinois、美国、61761
        • GSK Investigational Site
    • Louisiana
      • New Orleans、Louisiana、美国、20852
        • GSK Investigational Site
    • Maine
      • Bangor、Maine、美国、04401
        • GSK Investigational Site
    • Michigan
      • Detroit、Michigan、美国、48202
        • GSK Investigational Site
      • Warren、Michigan、美国、48088
        • GSK Investigational Site
    • Montana
      • Missoula、Montana、美国、59804
        • GSK Investigational Site
    • Nebraska
      • Papillion、Nebraska、美国、68046
        • GSK Investigational Site
    • New Jersey
      • Brick、New Jersey、美国、08724
        • GSK Investigational Site
      • Linwood、New Jersey、美国、08221
        • GSK Investigational Site
    • New York
      • New Windsor、New York、美国、12553-7754
        • GSK Investigational Site
    • North Carolina
      • Asheville、North Carolina、美国、28801
        • GSK Investigational Site
      • Charlotte、North Carolina、美国、28273
        • GSK Investigational Site
      • Greenville、North Carolina、美国、27834
        • GSK Investigational Site
      • Winston-Salem、North Carolina、美国、27104
        • GSK Investigational Site
    • Ohio
      • Cincinnati、Ohio、美国、45231
        • GSK Investigational Site
    • Pennsylvania
      • DuBois、Pennsylvania、美国、15801-2277
        • GSK Investigational Site
      • Philadelphia、Pennsylvania、美国、19140
        • GSK Investigational Site
      • Pittsburgh、Pennsylvania、美国、15241
        • GSK Investigational Site
    • South Carolina
      • Rock Hill、South Carolina、美国、29732
        • GSK Investigational Site
      • Spartanburg、South Carolina、美国、29303-4225
        • GSK Investigational Site
    • Texas
      • Beaumont、Texas、美国、77701
        • GSK Investigational Site
      • Dallas、Texas、美国、75225
        • GSK Investigational Site
    • Washington
      • Bellingham、Washington、美国、98225
        • GSK Investigational Site
  • 阿根廷
      • Buenos Aires、阿根廷、C1425BEN
        • GSK Investigational Site
      • Buenos Aires、阿根廷、C1128AAF
        • GSK Investigational Site
      • Buenos Aires、阿根廷、C1192AAW
        • GSK Investigational Site
      • Buenos Aires、阿根廷、FVH1425
        • GSK Investigational Site
      • Ciudad Autonoma de Buenos Aire、阿根廷、1012
        • GSK Investigational Site
      • Concepción del Uruguay、阿根廷、3260
        • GSK Investigational Site
      • Córdoba、阿根廷、X5003DCE
        • GSK Investigational Site
      • Formosa、阿根廷、3600
        • GSK Investigational Site
      • Lujan de Cuyo、阿根廷、5509
        • GSK Investigational Site
      • Luján、阿根廷、6700
        • GSK Investigational Site
      • Mar del Plata、阿根廷、7600
        • GSK Investigational Site
      • Mendoza、阿根廷、5500
        • GSK Investigational Site
      • Mendoza、阿根廷、5577
        • GSK Investigational Site
      • Mendoza、阿根廷、M5500
        • GSK Investigational Site
      • Quilmes、阿根廷、1878
        • GSK Investigational Site
      • Rosario、阿根廷、2000
        • GSK Investigational Site
      • Rosario、阿根廷、S2000DBS
        • GSK Investigational Site
      • Rosario、阿根廷、S2000 DEJ
        • GSK Investigational Site
      • San Juan Bautista、阿根廷、1888
        • GSK Investigational Site
      • San Miguel de Tucumán、阿根廷、T4000AXL
        • GSK Investigational Site
      • Santa Fe、阿根廷、3000
        • GSK Investigational Site
  • 韩国
      • Busan、韩国、602 702
        • GSK Investigational Site
      • Daegu、韩国、41404
        • GSK Investigational Site
      • Seongnam-si Gyeonggi-do、韩国、13620
        • GSK Investigational Site
      • Seoul、韩国、03080
        • GSK Investigational Site
      • Seoul、韩国、02841
        • GSK Investigational Site
      • Seoul、韩国、133-792
        • GSK Investigational Site
      • Seoul、韩国、158-710
        • GSK Investigational Site
      • Seoul、韩国、07061
        • GSK Investigational Site
      • Seoul、韩国、5030
        • GSK Investigational Site
      • Suwon Kyunggi-do、韩国、16499
        • GSK Investigational Site

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

Participants are eligible to be included in the study only if all of the following criteria apply:

  1. Has a diagnosis of asthma as defined by Global Initiative for Asthma (GINA) 2023 guidelines for at least 3 months prior to randomization.

  2. Participants who are either:

    • Currently untreated
    • Treated with daily maintenance ICS or ICS/LABA

  3. ACQ-6 score ≥1.5 at randomization.

  4. Participants able to perform technically acceptable and repeatable FEV1 maneuvers (i.e., a minimum of 2 acceptable and 1 repeatable effort) at visit 2 (V2)

  5. Participants must be able to complete the study questionnaires.

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  1. Recent history of life-threatening asthma
  2. History of >1 severe exacerbation of asthma within 12 months prior to randomization.
  3. Women of childbearing potential that are not following at least one highly effective method of contraception. This includes women who are pregnant or lactating or are planning on becoming pregnant during the study.
  4. A WOCBP must have a negative pregnancy test ≤7 days prior to randomization.
  5. Exposure to inhaler triple therapy [ICS + Long-acting muscarinic antagonist (LAMA) + LABA as Single inhaler triple therapy (SITT) or Multiple inhaler triple therapy(MITT)] and/or any LAMA-containing therapy within 12 months prior to randomization.
  6. Ongoing need for biologic therapy or recent use of a biologic therapy
  7. Participants with the diagnosis of chronic obstructive pulmonary disease, as per Global Initiative for Chronic Obstructive Lung Disease (GOLD 2024) guidelines.
  8. Participants whose current medications include RELVAR ELLIPTA and ARNUITY ELLIPTA are not eligible to enter the study.
  9. Participants who are medically unable to withhold their albuterol/salbutamol for 6 hours prior to spirometry testing
  10. Changes in asthma medication (e.g., maintenance ICS/LABA) within 3 months prior to randomization.
  11. Participants with a history of hypersensitivity to any of the study medications

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：无（打开标签）

武器和干预

参与者组/臂
干预/治疗
实验性的：Fluticasone Furoate [FF]/ Umeclidinium [UMEC]/ Vilanterol [VI]

Participants with uncontrolled asthma were randomized to receive a once-daily (QD) fixed-dose combination of 100 microgram (mcg) fluticasone furoate (FF), 62.5 mcg umeclidinium (UMEC), and 25 mcg vilanterol (VI) via the Ellipta dry powder inhaler (DPI) for up to 24 weeks. At the discretion of the investigator, a subset of participants received the high-dose ICS-containing therapy, FF/UMEC/VI 200/62.5/25 instead. At any time during the study (post-randomization), participants were escalated to receive FF/UMEC/VI 200/62.5/25 mcg if their asthma control worsened significantly, defined as an increase in Asthma Control Questionnaire (ACQ-7) total score of >0.5 from baseline and the physician determines increased Inhaled Corticosteroid [ICS] is ethically necessary.
药品：Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate

Participants will receive FF/UMEC/VI
有源比较器：Inhaled Corticosteroid [ICS]/Long-acting beta-2 agonist [LABA]

Participants with uncontrolled asthma were randomized to receive Inhaled Corticosteroid [ICS]/Long-acting beta-2 agonist [LABA] based on usual care as per the country specific regulatory labels up to 24 weeks. At the discretion of the investigator, a subset of participants received high-dose ICS/LABA. At any time during the study (post-randomization), participants were escalated to receive high dose ICS/LABA if their asthma control worsened significantly, defined as an increase in ACQ-7 total score of >0.5 from baseline and the physician determines increased ICS is ethically necessary.
药品：Inhaled corticosteroids/long-acting beta-2 agonists

Participants will receive ICS/LABA

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Change From Baseline (CFB) in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24
大体时间：Baseline (Day 1) and at Week 24

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value
Baseline (Day 1) and at Week 24

次要结果测量

结果测量
措施说明
大体时间
Percentage of Participants Achieving Greater Than Equal to (>=) 0.5 Point Improvement (Decrease) From Baseline for the Asthma Control Questionnaire-7 (ACQ-7) at Week 24
大体时间：Baseline (Day 1) and at Week 24

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation).ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to (<=)0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score >=1.5 indicates poorly controlled asthma. Greater than or equal to 0.5 point decrease from baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Percentage values are rounded off.
Baseline (Day 1) and at Week 24
Percentage of Participants Achieving the Composite Endpoint (Optimized) at Week 52
大体时间：Baseline (Day 1) and at Week 52

The 4-point composite endpoint is defined as meeting the following criteria: Change from baseline in trough FEV1 >= 100 milliliter (mL) at Week 52, Controlled asthma based on ACQ-5 total score <= 1.5 at Week 52, No severe asthma exacerbations over 52 weeks and oral corticosteroids (OCS)-free over 52 weeks
Baseline (Day 1) and at Week 52
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 52
大体时间：Baseline (Day 1) and at Week 52

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1).
Baseline (Day 1) and at Week 52
Percentage of Participants With Change From Baseline in Trough FEV1 >= 100 mL at Week 24
大体时间：Baseline (Day 1) and at Week 24

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value. Percentage values are rounded-off.
Baseline (Day 1) and at Week 24
Percentage of Participants With Change From Baseline in Trough FEV1 >= 100 mL at Week 52
大体时间：Baseline (Day 1) and at Week 52

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1).
Baseline (Day 1) and at Week 52
Percentage of Participants With Change From Baseline in Trough FEV1 >= 0 mL at Week 24
大体时间：Baseline (Day 1) and at Week 24

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value. Percentage values are rounded-off.
Baseline (Day 1) and at Week 24
Percentage of Participants With Change From Baseline in Trough FEV1 >= 0 mL at Week 52
大体时间：Baseline (Day 1) and at Week 52

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1).
Baseline (Day 1) and at Week 52
Percentage of Participants Achieving >= 0.5 Point Improvement (Decrease) From Baseline for the ACQ-7 Score at Week 52
大体时间：Baseline (Day 1) and at Week 52

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to (<=) 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score >= 1.5 indicates poorly controlled asthma. Greater than or equal to 0.5 point decrease from baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52
Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-6 Score at Week 24
大体时间：Baseline (Day 1) and at Week 24

The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of <=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores >=1.5 indicate poorly controlled asthma. A decrease in ACQ-6 score from Baseline indicates an improvement in asthma control, and individual changes of at least 0.5 are considered clinically meaningful. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Percentage values are rounded off.
Baseline (Day 1) and at Week 24
Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-6 Score at Week 52
大体时间：Baseline (Day 1) and at Week 52

The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of <=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores >=1.5 indicate poorly controlled asthma. A decrease in ACQ-6 score from Baseline indicates an improvement in asthma control, and individual changes of at least 0.5 are considered clinically meaningful. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52
Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-5 Score at Week 24
大体时间：Baseline (Day 1) and at Week 24

The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/ limitation. Higher scores indicated more limitations and lower scores indicated better asthma control. Higher score indicates worse symptoms. Greater than or equal to 0.5 point decrease from baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Percentage values are rounded-off.
Baseline (Day 1) and at Week 24
Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-5 at Week 52
大体时间：Baseline (Day 1) and at Week 52

The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/ limitation. Higher scores indicated more limitations and lower scores with better asthma control. Higher score indicates worse symptoms. Greater than or equal to 0.5 point decrease from Baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the ACQ-7 Total Score at Week 24
大体时间：Baseline (Day 1) and at Week 24

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score >=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value
Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the ACQ-7 Total Score at Week 52
大体时间：Baseline (Day 1) and at Week 52

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score >=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the ACQ-6 Total Score at Week 24
大体时间：Baseline (Day 1) and at Week 24

The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of <=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores >=1.5 indicate poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the ACQ-6 Total Score at Week 52
大体时间：Baseline (Day 1) and at Week 52

The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of <=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores >=1.5 indicate poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the ACQ-5 Total Score at Week 24
大体时间：Baseline (Day 1) and at Week 24

The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/limitation. Higher scores indicated more limitations and lower scores indicated better asthma control. Higher score indicates worse symptoms. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the ACQ-5 Total Score at Week 52
大体时间：Baseline (Day 1) and at Week 52

The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/limitation. Higher scores indicated more limitations and lower scores indicated better asthma control. Higher score indicates worse symptoms. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the Asthma Control Test (ACT) Score at Week 24
大体时间：Baseline (Day 1) and at Week 24

The ACT is a validated self-completed questionnaire utilizing 5 questions to assess asthma control on a 5-point categorical scale ranging from 1 (not controlled at all) to 5 (completely controlled) with higher scores indicating better control. Total ACT score is calculated as the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 15 suggests that the participant's asthma is poorly controlled, a score of 16 to 19 suggests that the participant's asthma is somewhat controlled, and a score of 20 to 25 suggests that the participant's asthma is well controlled. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. CFB was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the Asthma Control Test (ACT) Score at Week 52
大体时间：Baseline (Day 1) and at Week 52

The ACT is a validated self-completed questionnaire utilizing 5 questions to assess asthma control on a 5-point categorical scale ranging from 1 (not controlled at all) to 5 (completely controlled) with higher scores indicating better control. Total ACT score is calculated as the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 15 suggests that the participant's asthma is poorly controlled, a score of 16-to 19 suggests that the participant's asthma is somewhat controlled, and a score of 20 to 25 suggests that the participant's asthma is well controlled. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52
Percentage of Participants Achieving the Composite Endpoint (Optimized) Subset on Participants Receiving ICS/LABA Prior to Randomization at Week 52
大体时间：Baseline (Day 1) and at Week 52

The 4-point composite endpoint is defined as meeting the following criteria: 1. Change from baseline in trough FEV1 ≥ 100 mL at Week 52; 2. Controlled asthma based on ACQ-5 total score <= 1.5 at Week 52; 3. No severe asthma exacerbations over 52 weeks; 4. OCS-free over 52 weeks. Subset on participants receiving ICS/LABA prior to randomization.
Baseline (Day 1) and at Week 52
Percentage of Participants Achieving the Composite Endpoint (Optimized) Subset on Participants Receiving no Treatment Prior to Randomization at Week 52
大体时间：Baseline (Day 1) and at Week 52

The 4-point composite endpoint is defined as meeting the following criteria: 1. Change from baseline in trough FEV1 ≥ 100 mL at Week 52; 2. Controlled asthma based on ACQ-5 total score <= 1.5 at Week 52; 3. No severe asthma exacerbations over 52 weeks; 4. OCS-free over 52 weeks. Subset on participants receiving no treatment prior to randomization (no ICS-containing therapy within the 3 months prior to randomization).
Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Total Score at Week 24
大体时间：Baseline (Day 1) and at Week 24

AQLQ-12 is a disease-specific, self-administered quality of life questionnaire used to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), environmental stimuli (4 items). For 32 items on questionnaire, response format consists of a 7-point scale, where 1 indicates "total impairment" and 7 indicates "no impairment." AQLQ-12 total score is defined as average of scores from all 32 questions; thus, total score ranges from 1="total impairment" to 7=indicates "no impairment". Higher score is better asthma-related health-related quality of life. Baseline is last non-missing value prior to or on prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Total Score at Week 52
大体时间：Baseline (Day 1) and at Week 52

AQLQ-12 is a disease-specific, self-administered quality of life questionnaire to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), environmental stimuli (4 items). For 32 items on questionnaire, response format consists of a 7-point scale, where a value of 1 indicates "total impairment" and a value of 7 indicates "no impairment." AQLQ-12 total score is defined as average of scores from all 32 questions; thus, total score ranges from 1="total impairment" to 7="no impairment". Higher score is better asthma-related health-related quality of life. Baseline is last non-missing value prior to or on prescription date of study intervention.
Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Domain Score at Week 24
大体时间：Baseline (Day 1) and at Week 24

AQLQ-12 is a disease-specific, self-administered quality of life questionnaire used to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: symptoms (12 items), environmental stimuli (4 items), activity limitation (11 items), emotional function (5 items). For 32 items on questionnaire, response format consists of a 7-point scale, where 1 indicates "total impairment" and 7 indicates "no impairment." AQLQ-12 each domain score total score is defined as average of scores from all the 32 questions from the respective domain; thus, each domain total score ranges from 1="total impairment" to 7=indicates "no impairment". Higher score is better asthma-related health-related quality of life. Each domain score is the mean of item scores within that domain. Baseline is last non-missing value prior to or on prescription date of study intervention. CFB was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Domain Score at Week 52
大体时间：Baseline (Day 1) and at Week 52

AQLQ-12 is a disease-specific, self-administered quality of life questionnaire used to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: symptoms (12 items), environmental stimuli (4 items), activity limitation (11 items), emotional function (5 items). For 32 items on questionnaire, response format consists of a 7-point scale, where 1 indicates "total impairment" and 7 indicates "no impairment." AQLQ-12 each domain score total score is defined as average of scores from all the 32 questions from the respective domain; thus, each domain total score ranges from 1="total impairment" to 7=indicates "no impairment". Higher score is better asthma-related health-related quality of life. Each domain score is the mean of item scores within that domain. Baseline is last non-missing value prior to or on prescription date of study intervention.
Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the Four Domains of the Asthma-specific Adaptation of the Work Productivity and Activity Impairment (WPAI) Questionnaire at Week 24
大体时间：Baseline (Day 1) and at Week 24

WPAI questionnaire measures impact due to poor health due to asthma on work and regular activities, yielding 4 percentage-based impairment scores, each ranges from 0 to 100%. Higher values=greater impairment and less productivity. Calculation of these 4 scores are as follows: 1. Work time missed due to health (Absenteeism)=hours missed due to health divided by (hours missed due to health+hours missed for other reasons+hours actually worked) *100. 2. Impairment while working due to health (Presenteeism) =Question (Q)5 score (from 0 to 10) divided by 10*100. 3. Overall work impairment due to health =Absenteeism+(1-Absenteeism fraction)*Presenteeism. 4. Activity impairment due to health =Q6 score (from 0 to 10) divided by 10*100. Baseline is last non-missing value prior to or on prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
Baseline (Day 1) and at Week 24
Change From Baseline in the Four Domains of the Asthma-specific Adaptation of the Work Productivity and Activity Impairment Questionnaire at Week 52
大体时间：Baseline (Day 1) and at Week 52

WPAI questionnaire measures impact due to poor health due to asthma on work and regular activities, yielding 4 percentage-based impairment scores, each ranges from 0 to 100%. Higher value=greater impairment and less productivity. Calculation of these 4 scores are as follows: 1. Work time missed due to health (Absenteeism) =hours missed due to health divided by (hours missed due to health+hours missed for other reasons+hours actually worked) *100. 2. Impairment while working due to health (Presenteeism) =Question (Q)5 score (from 0 to 10) divided by 10*100. 3. Overall work impairment due to health =Absenteeism+(1-Absenteeism fraction)*Presenteeism. 4. Activity impairment due to health =Q6 score (from 0 to 10) divided by 10*100. Baseline is last non-missing value prior to or on prescription date of study intervention.
Baseline (Day 1) and at Week 52
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 Among Participants on ICS/LABA Prior to Randomization
大体时间：Baseline (Day 1) and Week 24

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study (EOS) date.
Baseline (Day 1) and Week 24
Percentage of Participants Achieving >=0.5 Points Improvement (Decrease) From Baseline for ACQ-7 at Week 24 Among Participants on ICS/LABA Prior to Randomization
大体时间：Baseline (Day 1) and at Week 24

The ACQ-7 measures 7 attributes of asthma control & includes 5 symptom questions (nocturnal awakening,symptoms on waking in morning,activity limitation,shortness of breath & wheeze). Responses ranges from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of the responses of 7 items, ranges from 0 to 6. Higher score = poor control. A score of <= 0.75 is well-controlled asthma; a score between 0.75 and 1.5 is partially controlled asthma & a score >= 1.5 is poorly controlled asthma. >= 0.5 point decrease from baseline is clinically important change in asthma control. Baseline is last non-missing value prior to or on the prescription date of study intervention. Per Protocol study's subgroup analysis design, analysis for this endpoint at Week 24 will be performed based on results from composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of EOS date.
Baseline (Day 1) and at Week 24
Percentage of Participants Achieving >=0.5 Points Improvement (Decrease) From Baseline for ACQ-7 at Week 52 Among Participants on ICS/LABA Prior to Randomization
大体时间：Baseline (Day 1) and at Week 52

The ACQ-7 measures 7 attributes of asthma control & includes 5 symptom questions (nocturnal awakening,symptoms on waking in the morning,activity limitation,shortness of breath & wheeze). Responses ranges from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of the responses of the 7 items, ranges from 0 to 6. Higher score = poor control. A score of <= 0.75 is well-controlled asthma; a score between 0.75 and 1.5 is partially controlled asthma & a score >= 1.5 is poorly controlled asthma. >= 0.5 point decrease from baseline is clinically important change in asthma control. Baseline is last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52
Change From Baseline in the ACQ-7 Total Score at Week 24 Among Participants on ICS/LABA Prior to Randomization
大体时间：Baseline (Day 1) and at Week 24

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score between 0.75 and 1.5 indicates partially controlled asthma, and a score >=1.5 indicates poorly controlled asthma. Baseline is defined as last non-missing value prior to or on prescription date of study intervention. Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.
Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the ACQ-7 Total Score at Week 52 Among Participants on ICS/LABA Prior to Randomization
大体时间：Baseline (Day 1) and at Week 52

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score between 0.75 and 1.5 indicates partially controlled asthma, and a score >=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 for Participants With no Treatment Prior to Randomization
大体时间：Baseline (Day 1) and Week 24

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.
Baseline (Day 1) and Week 24
Percentage of Participants Achieving >=0.5 Points Improvement (Decrease) From Baseline for ACQ-7 at Week 24 for Participants With no Treatment Prior to Randomization.
大体时间：Baseline (Day 1) and at Week 24

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of <=0.75 indicates well-controlled asthma and a score >=1.5 indicates poorly controlled asthma. >= 0.5 point decrease from baseline is clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.
Baseline (Day 1) and at Week 24
Percentage of Participants Achieving >=0.5 Points Improvement (Decrease) From Baseline for ACQ-7 at Week 52 for Participants With no Treatment Prior to Randomization
大体时间：Baseline (Day 1) and at Week 52

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). Response ranges from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of the responses of 7 items, ranges from 0 to 6. Higher score = poor control. A score of <=0.75 indicates is well-controlled asthma; and a score >=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the ACQ-7 Total Score at Week 24 for Participants With no Treatment Prior to Randomization
大体时间：Baseline (Day 1) and at Week 24

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of less than equal to 0.75 indicates well-controlled asthma, a score between 0.75 and 1.5 indicates partially controlled asthma, and a score >=1.5 indicates poorly controlled asthma. A change of 0.5 in score suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.
Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the ACQ-7 Total Score at Week 52 for Participants With no Treatment Prior to Randomization
大体时间：Baseline (Day 1) and at Week 52

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of less than equal to 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score >=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

GlaxoSmithKline

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年4月16日

初级完成 (实际的)

2025年7月28日

研究完成 (估计的)

2027年6月14日

研究注册日期

首次提交

2024年4月15日

首先提交符合 QC 标准的

2024年4月15日

首次发布 (实际的)

2024年4月18日

研究记录更新

最后更新发布 (实际的)

2026年10月6日

上次提交的符合 QC 标准的更新

2026年9月11日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • 219912

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

是的

IPD 计划说明

Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

IPD 共享时间框架

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

IPD 共享访问标准

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅